Hypoallergenic Infant Formula Containing Starch and the Probiotic: Effect on Gastric Emptying

NCT ID: NCT01956682

Last Updated: 2015-04-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

132 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-10-31

Study Completion Date

2015-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this trial is to show that an hypoallergenic infant starter formula containing starch and the probiotic L. reuteri decreases the severity of regurgitation/spitting-up in infants presenting regurgitation/spitting-up , and who have taken it for 4 weeks, in comparison with a standard infant starter formula.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of this trial is to show that the test formula (HA formula + starch + L. reuteri) decreases the severity (frequency + volume) of regurgitation/spitting-up in infants and ultrasound gastric emptying time, compared to a classical infant starter formula.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Regurgitation, Gastric

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Infant formula

HA formula + starch + L. reuteri

Group Type ACTIVE_COMPARATOR

HA formula + starch + L. reuteri

Intervention Type DIETARY_SUPPLEMENT

Standard Formula

Standard Infant Formula

Group Type PLACEBO_COMPARATOR

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HA formula + starch + L. reuteri

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Full term infant (37 weeks ≤ gestation ≤ 42 weeks)
* Age of infant between 5 days and 5 months
* NGA
* Infant exclusively formula-fed at enrollment
* Presenting regurgitation/spitting-up according to the parents' perception
* Vandenplas score of at least 2 and maximum 5
* Having obtained the subject's legal representative's written informed consent

Exclusion Criteria

* Previous antireflux treatment
* Previous consumption of AR infant formula or external thickener
* Previous consumption of a formula with L. reuteri
* Cow's milk allergy symptoms according to medical decision
* Congenital illness or malformation that may affect growth
* Significant pre-natal and/or post-natal disease
* Newborn whose parents / caregivers cannot be expected to comply with study procedures
* Newborn currently participating or having participated in another clinical trial during the last 4 weeks prior to the beginning of this study.
Minimum Eligible Age

5 Days

Maximum Eligible Age

5 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Bari

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Flavia Indrio

M.D.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Flavia Indrio, MD

Role: PRINCIPAL_INVESTIGATOR

University of Bari

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ospedale Pediatrico Giovanni XXIII

Bari, BA, Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

University of Bari

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Prevention of Allergic Diseases in Infants
NCT03489733 ACTIVE_NOT_RECRUITING NA